**14. Summary**


Current Overview of COPD with Special Reference to Emphysema 151

ATS Public Policy Statement,(2010): Novel risk factors and the global burden of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* ;182:693–718. Bates DV, ed(1989). In: *Respiratory Function in Disease*. 3rd ed. Philadelphia: WB Saunders; . Boas SR, Winnie GB (2011). Emphysema and Overinflation. In: *Nelson Textbook of* 

Bourdin A, Burgel PR, Chanez P et al,(2009) Recent advances in COPD: pathophysiology,

BTS,(1997). BTS guidelines for the management of chronic obstructive pulmonary disease.

Buist AS, McBurnie MA, Vollmer WM, et al.(2007) International variation in the prevalence

Calverley PM, Anderson JA, Celli B, et al(2007): Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* ; 356:775-789. Celli BR, Cote CG, Marin JM, et al(2004): The body-mass index, airflow obstruction,

CIAS Group(1994): In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. *Chest* ; 105:1411-1419. Connors Jr AF, Dawson NV, Thomas C, et al(1996): Outcomes following acute exacerbation

Fletcher C, Peto R, Tinker C, Speizer FE, ed.(1976) In: *The Natural History of Chronic Bronchitis* 

Global Initiative for Chronic Obstructive Lung Disease (GOLD).(2006)Global strategy for the

Jones PW, Quirk FH, Baveystock CM(1991): The St George's Respiratory Questionnaire.

Kvale PA, Cugell DW, Anthonisen NR, et al(1980): Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. *Ann Intern Med* ; 93:391-398. Mannino DM, Buist AS(2007): Global burden of COPD: Risk factors, prevalence, and future

Medical Research Council Working Party(1981)- Report of.Long-term domiciliary oxygen

NETT (1999)Rationale and design of the National Emphysema Treatment Trial : A

Reid LM(1960): Measurement of bronchial mucous gland layer. A diagnostic yardstick in

therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and

prospective randomized trial of lung volume reduction surgery. *J Thorac Cardiovasc* 

respiratory physiology and clinical aspects, including comorbidities *Eur Respir Rev*;

The COPD Guidelines Group of the Standards of Care Committee of the BTS.

of COPD (the BOLD Study): a population-based prevalence study. *Lancet*. Sep 1

dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N* 

of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am* 

diagnosis, management, and prevention of chronic obstructive pulmonary disease: Executive summary . http://www.goldcopd.org (Accessed on August 15, 2011). Guyatt GH, Berman LB, Townsend M, et al(1987): A measure of quality of life for clinical

*Pediatrics*,19th ed, Kleigman.

18: 114, 198–212.

;370(9589):741-50.

*Thorax* ; 52 Suppl 5:S1.

*Engl J Med 350:1005–1012.* 

*J Respir Crit Care Med* ; 154:959-967.

trends. *Lancet* ; 370:765-773.

*Surg* ; 118:518-528.

emphysema. *Lancet* ; 1:681-686.

*and Emphysema*, New York: Oxford University Press; .

trials in chronic lung disease. *Thorax* ; 42:773-778.

Petty TL: Simple office spirometry. *Clin Chest Med* 2001; 22:845-859.

chronic bronchitis. *Thorax* ; 15:132-141.

*Respir Med* ; 85(Suppl B):25-31.[discussion 3–7]

extracellular matrix injury which heals with incomplete and disorganized repair mechanisms ultimately leading to permanent progressive airflow obstruction. Deficiency of anti-protease deficiency makes individuals particularly susceptible to this pathologic process with earlier and more severe disease presentation.

